Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
A 3-SNP GRS and MetRS were generated in the EPIC-Norfolk cohort (n = 20,074) based on 3 SNPs in LPL and APOA5 or the number of Metabolic Syndrome criteria present (maximum 5), respectively.
|
30910668 |
2020 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lipoprotein lipase (LPL) hydrolyzes triglycerides in lipoprotein to supply fatty acids, and its deficiency leads to hypertriglyceridemia, thereby inducing metabolic syndrome (MetSyn).
|
31234537 |
2019 |
Metabolic Syndrome X
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Significant increases were observed in blood pressure, HOMA-IR, leptin, triglycerides, insulin, intra-abdominal fat, and number of fat cells per field (<i>p</i> = 0.001) and in advanced glycosylation products, adipocyte area, LPL, HSL activities and/or expression (<i>p</i> ≤ 0.01) in the MS groups progressively from the third month onward.
|
31284400 |
2019 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Gender-related relation between metabolic syndrome and S447X and HindIII polymorphisms of lipoprotein lipase gene in northern Iran.
|
31034941 |
2019 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations in the lipoprotein lipase gene causing decreased lipoprotein lipase activity are associated with surrogate markers of insulin resistance and the metabolic syndrome in humans.
|
28502509 |
2018 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The apolipoprotein A5 Q139X, lipoprotein lipase (LPL) Hinf I, human paraoxonase 1 (PON1) 192Arg/Gln, cholesteryl ester transfer protein (CETP) Taq1B, adiponectin 45T>G and leptin (LEP) 25CAG were genotyped by real-time polymerase chain reaction in participants with and without MetS.
|
30381540 |
2018 |
Metabolic Syndrome X
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The aim of this study was to analyze the level of DNA methylation of several lipoprotein lipase (LPL)-promoter-CpG dinucleotides in a CpG island region and relate this to the gene and protein expression levels in human visceral adipose tissue (VAT) from individuals with and without MetS.
|
29046332 |
2018 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Multiple genotype-phenotype association study reveals intronic variant pair on SIDT2 associated with metabolic syndrome in a Korean population.
|
30382898 |
2018 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The LPL polymorphism contributed to the severity of coronary disease in patients with MS and recent ACS.
|
29412239 |
2018 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Increased risk of developing metabolic syndrome (MetS) has been associated with the APOA5, APOC1, BRAP, BUD13, CETP, LIPA, LPL, PLCG1, and ZPR1 genes.
|
27827461 |
2016 |
Metabolic Syndrome X
|
0.400 |
Therapeutic
|
disease |
RGD |
Gly in MS rats decreased body weight, intra-abdominal adipose tissue, adipocyte hypertrophy, blood pressure, triglycerides, insulin, HOMA-IR index, leptin, total fatty acids, non-esterified fatty acids and LPL activity.
|
26996629 |
2016 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study investigated the relationship between two common LPL variants and the presence of MetS and its individual components.
|
27676127 |
2016 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, we replicated the LPL and CETP loci previously found to be associated with MetS in Europeans.
|
26507551 |
2015 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results show the involvement of the variants of ESR1, LPL and CETP genes in metabolic events related to MetS or some of its features.
|
26370976 |
2015 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A novel African American-specific variant, rs12721054/APOC1, and rs10096633/LPL are associated with ≥3 MetS components.
|
25023634 |
2014 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the group of participants with PPARγ Pro12Ala or Ala12Ala genotypes, those with the LPL Pvu (-/+) or (+/+) genotype had greater odds for MetSy (odds ratio OR=5.98; 95% confidence interval CI: 1.46-24.47, p=0.013).
|
24200052 |
2014 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
LPL mass was significantly lower in patients with PvuII and HindIII mutant alleles (P2 and H2) and decreased as the number of MetSyn components increased in all PvuII and HindIII haplotypes.
|
23927945 |
2013 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.
|
22399527 |
2012 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.
|
22399527 |
2012 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
This was the first study this kind to show an association between LPL and large VLDL particle size within the MetS, a pattern associated with higher IR.
|
21854610 |
2011 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.
|
21386085 |
2011 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma fatty acid composition, plasma lipid concentrations and LPL SNPs were determined in 452 subjects with the MetS in the European LIPGENE human study and were repeated in 1754 subjects from the LIPGENE-SU.VI.MAX Study.
|
21840003 |
2011 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
GWASDB |
A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.
|
21386085 |
2011 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Logistic regression analysis after adjustment for age, sex, adiponectin and S447X polymorphism demonstrated that LPL mass was inversely associated with CHD in men and both genders (p=0.02), with hypertension confined to women (p=0.04) and with MS likelihood in both genders combined and women [odds ratio 1.51 (95% CI 1.14-2.00) for halving the likelihood].
|
19191728 |
2009 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We assessed lipid levels and the frequencies of the cholesteryl ester transfer protein (CETP) Taq-1 B, lipoprotein lipase (LPL)S447X, -93 T/G, apolipoprotein B (APO B) 96bp ins/del, lipoprotein(a) (LP[a]) pentanucleotide repeat, and apolipoprotein E (APO) E epsilon 2/3/4 polymorphisms in relation to the metabolic syndrome using both National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and International Diabetes Federation (IDF) definitions.
|
19642912 |
2009 |